微小RNA-331的表达可作为急性髓系白血病患者治疗反应和生存情况的预测指标。
Expression of microRNA-331 can be used as a predictor for response to therapy and survival in acute myeloid leukemia patients.
作者信息
Butrym Aleksandra, Rybka Justyna, Baczyńska Dagmara, Tukiendorf Andrzej, Kuliczkowski Kazimierz, Mazur Grzegorz
机构信息
2Department of Physiology, Wroclaw Medical University, Chałubinski 10 Str, 50-368 Wroclaw, Poland.
3Department of Forensic Medicine, Molecular Techniques Unit, Wroclaw Medical University, Curie-Sklodowskiej 52 Str, 50-369 Wroclaw, Poland.
出版信息
Biomark Med. 2015;9(5):453-60. doi: 10.2217/bmm.14.112. Epub 2015 Jan 26.
AIM
Aberrant expression of microRNAs (miRs) has been proved to have a role in acute myeloid leukemias (AML), but there is no information on miR-331 in AML.
MATERIALS & METHODS: miR-331 expression has been analyzed using reverse-transcription polymerase chain reaction (RT-PCR) in 95 bone marrow specimens from newly diagnosed AML patients in comparison with 20 healthy subjects.
RESULTS
miR-331 was upregulated in AML patients and its expression seemed to influence remission achieving and death risk. The time of remission duration in patients with complete remission was longer in subjects with miR-331 downregulation after induction chemotherapy.
CONCLUSION
we showed for the first time that miR-331 higher expression appears to be correlated with worse response to therapy and shorter survival of AML patients.
目的
已证实微小RNA（miR）的异常表达在急性髓系白血病（AML）中发挥作用，但关于AML中miR-331的信息尚无报道。
材料与方法
采用逆转录聚合酶链反应（RT-PCR）分析了95例新诊断AML患者骨髓标本中miR-331的表达，并与20名健康受试者进行比较。
结果
miR-331在AML患者中上调，其表达似乎影响缓解的实现和死亡风险。诱导化疗后miR-331下调的完全缓解患者的缓解持续时间更长。
结论
我们首次表明，miR-331高表达似乎与AML患者对治疗的反应较差和生存期较短相关。
Zotero 插件